Asset
TRAVOPROST
Glaukos Corporation Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04615403 | phase2 | completed | 2020-11-19 | 2022-02-28 | Glaukos Corporation | Study of Exchange of Travoprost Intraocular Implant |
| NCT01444040 | phase4 | completed | 2011-09-01 | 2019-03-28 | Glaukos Corporation | Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost |
| NCT01443988 | phase4 | completed | 2011-09-01 | 2017-01-01 | Glaukos Corporation | Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost |
| NCT06061718 | phase3 | unknown | 2023-09-11 | 2024-03-18 | Glaukos Corporation | Travoprost Intraocular Implant in Conjunction With Cataract Surgery |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 218010 | NDA | GLAUKOS CORP |
Marketed products (1)
- IDOSE TR